D.A.T.E.: Over-allotment option exercised in full, free float raised to approximately 33% of capital

751,420 shares offered, a free float of approximately 33%

The existing ordinary shares were sold at the offering price of €19.36 per share. In total, 751,420 shares were offered during the initial public offering on Euronext Growth in Paris: 601,756 new shares and 149,664 existing shares as part of the offering and over-allotment option. The free float now represents approximately 33% of the company's capital.

Portzamparc (BNP Paribas group), acting as stabilizing agent, notified D.A.T.E. that it had not carried out any stabilization operations within the meaning of Article 3.2(d) of Regulation (EU) No. 596/2014, known as the "Market Abuse Regulation". The stabilization period, opened on September 25, 2026, ended on October 23, 2026.

Dopamine as majority shareholder, a liquidity contract entrusted to Portzamparc

On a non-diluted basis, Dopamine holds 1,435,256 shares, representing 63.7% of capital and 77.8% of voting rights, taking into account the double voting right established following the admission of securities on Euronext Growth. Management (Dopamine, Romain Vinot and Gilles Anelli) holds 66.7% of capital and 79.6% of voting rights, with the public holding 20.2% of voting rights. Capital consists of 2,254,156 shares, representing 3,689,412 voting rights.

D.A.T.E. has also entrusted Portzamparc with the implementation of a liquidity contract for a period of one year, renewable by tacit renewal, effective October 26, 2026. The sum of €200,000 in cash has been allocated to the liquidity account. The contract, established under AMF Decision No. 2021-01 of June 22, 2021, may be terminated by the company at any time and without notice, or by Portzamparc with one month's notice.

The company will publish its 2026 half-year results on October 27, 2026, before trading.